Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KIAA1671 antisense RNA 1 (KIAA1671-AS1) is a long non-coding RNA (lncRNA) gene located on chromosome 22 (chr22:25102417-25112716, hg38)[1][3]. It is classified as an antisense RNA—RNA molecules transcribed from the DNA strand opposite to the coding (sense) gene and is not translated into protein[7]. Like other naturally occurring antisense RNAs, KIAA1671-AS1 is implicated in the regulation of gene expression through various molecular mechanisms, which may include interaction with complementary messenger RNAs, modulation of chromatin structure, or influence on transcriptional processes[2][5]. The specific functional roles of KIAA1671-AS1 remain incompletely characterized, but diseases associated with dysregulation of this RNA include retinitis pigmentosa[3]. There are no known direct drug interactions, established uses as a biomarker, or documented safety concerns linked to targeting this RNA. Its principal molecular classification is as a long non-coding antisense RNA rather than as a protein-coding target such as a receptor, enzyme, or transporter[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KIAA1671 antisense RNA 1 (KIAA1671-AS1).